Commentary|Videos|May 28, 2026

Optimizing Biomarker-Driven Treatment and Immune Checkpoint Inhibitor Counseling in Endometrial Cancer

Name: Optimizing Biomarker-Driven Treatment and Immune Checkpoint Inhibitor Counseling in Endometrial Cancer
Uploaded: 2026-05-28T16:00:00Z
Duration: 5 min 21 s
Description: Optimizing Biomarker-Driven Treatment and Immune Checkpoint Inhibitor Counseling in Endometrial Cancer

Author(s)Erin Zacholski, PharmD, BCOP, Danielle Valletti, Assistant Editor

Fact checked by: Kirsty Mackay

Pharmacists play a big role in biomarker testing, patient selection, and counseling on immune checkpoint inhibitor therapy in endometrial cancer.

In this interview with Pharmacy Times, Erin Zacholski, PharmD, BCOP, assistant professor at Virginia Commonwealth University (VCU) School of Pharmacy, and clinical pharmacy specialist, gynecologic oncology at VCU Massey Comprehensive Cancer Center, discusses the growing importance of biomarker-driven treatment strategies in endometrial cancer. Zacholski emphasizes the pharmacist’s role in ensuring timely biomarker testing, including mismatch repair deficient/microsatellite instability–high status, HER2 overexpression, tumor mutational burden, RET alterations, and NTRK fusions, to guide treatment decisions and optimize frontline therapy selection. She also highlights key counseling strategies for immune checkpoint inhibitor–based therapy, including discussing survival benefits, immune-related adverse events, and long-term maintenance considerations with patients.

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME

Webinar Registration

Outsmart the Algorithm: Combatting Misinformation at the Pharmacy Counter

Wednesday, July 22, 2026 | 1:00 PM & 8:00 PM

Optimizing Biomarker-Driven Treatment and Immune Checkpoint Inhibitor Counseling in Endometrial Cancer

Related Content

Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier

Machine Learning Update to Martin-Hopkins Equation Improves LDL-C Accuracy for Labs

Rural Health Transformation Efforts Offer an Opportunity for Pharmacy to Shine

How AON Built an Outpatient BiTE Therapy Program for Multiple Myeloma

Expert Q&A: What the MMRV Vaccine Equity Data Means for Pharmacists

Latest CME

Outsmart the Algorithm: Combatting Misinformation at the Pharmacy Counter

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Managing Overactive Bladder in Older Adults: Challenges and Strategies for Long-Term Care

Bridging Clinical and Access Gaps in Phenylketonuria: A Managed Care Perspective

Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

Exploring Immunotherapy Strategies in Endometrial Cancer

Managing Steroid-Refractory Chronic Graft-versus-Host Disease With Novel Therapies: Opportunities for Pharmacist-Led Interventions

Best Practice Approaches for Understanding Chronic Obstructive Pulmonary Disease and Precision Medicine Treatment

HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

Advancing Patient Safety: Strategies to Address Safety Risks and Adherence Barriers to Optimize Outcomes for Patients on Injectable Therapies

Navigating the Complexities of Personalized Prostate Cancer Care: Insights for Oncology Managed Care

An American Journal of Managed Care Forum: Bridging Evidence and Access in Advanced Small Cell Lung Cancer

Advancing Chronic Kidney Disease Detection and Cardiovascular Risk Reduction in Complex Patients

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations (Pharmacy Technician Credit)

Artificial Intelligence in Pharmacy Practice: Validated Tools, Real-World Applications, and Emerging Innovations

Continuing the Conversation: Pharmacist Interventions to Optimize T2D Care and Break Through Clinical Inertia

Hat Trick for Hypertension: Strategies to Improve Outcomes With Single-Pill Combinations

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

New Horizons in ATTR-CM: Therapeutic Advances and Strategic Insights

Innovations in Retinal Therapies: A Managed Care Perspective on Anti-VEGF Advancements

Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Neuropsychiatry Day of Education 2026

Securing the Supply Chain: The Pharmacists’ Role in DSCSA Compliance

Breaking Barriers in Asthma Care: Exploring the Role of Type 2 Inflammation and Biologic Therapies

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Payment for Pharmacist Services: 2025 Update

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Lymphoma Day of Education 2026

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

Paroxysmal Nocturnal Hemoglobinuria: Managed Care Strategies to Mitigate Burden and Enhance Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

The Pharmacist's Role in Palliative and End of Life Symptom Management

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients (Pharmacy Technician Credit)

Understanding mRNA Vaccines: Dispelling Myths and Empowering Pharmacists to Counsel Patients

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

From Testing to Treatment: Empowering Pharmacists to Overcome Barriers and Optimize Biomarker-Driven Care

Clinical Presentation of Hyperglycemia with PI3K and AKT Inhibitors

Addressing Vaccine Hesitancy in Infectious Disease Prevention

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

The Expanding Therapeutic Landscape in IgA Nephropathy: Translating New Clinical Evidence and Updated Guidelines Into Managed Care Strategies

From Guidelines to Action: Implementing Pneumococcal Vaccine ACIP Recommendations in Long-Term Care Settings

Adapting to Advances in EGFR-Positive Non-Small Cell Lung Cancer Treatment: Critical Insights for Oncology Pharmacists

Expanding the Role of Long-Acting Injectables in Optimizing Schizophrenia Management

VMAT2 Inhibitors for Long-Term Success in Tardive Dyskinesia

Shifting Perspectives in Treatment-Resistant Depression: Novel Therapies and Patient-Centered Care

Navigating Adverse Effects in HR+/HER2-Negative Metastatic Breast Cancer: Tailored Management Plans and Pharmacist Interventions for Improved Outcomes

Bridging Knowledge Gaps in HR+/HER2– Early-Stage Breast Cancer

Optimizing HER2-Directed Therapy in Metastatic Breast Cancer: From HER2-Positive to HER2-Ultralow

Expert Insights on the Horizon of HER2-Directed Therapy

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

From Flares to Freedom: Navigating the Journey of Patients With Chronic Spontaneous Urticaria With Next-Generation Therapies

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy